Mohamad Raad, Haran Yogasundaram, Justice Oranefo, Gustavo Guandalini, Timothy Markman, Matthew Hyman, Robert Schaller, Gregory Supple, Rajat Deo, Saman Nazarian, Michael Riley, David Lin, Fermin Garcia, Sanjay Dixit, Andrew E Epstein, David Callans, Francis E Marchlinski, David S Frankel
BACKGROUND: Premature ventricular complexes (PVCs) are common and associated with worse outcomes in patients with heart failure. Class 1C antiarrhythmic drugs (AADs) effectively suppress PVCs, but guidelines currently restrict their use in structural heart disease. OBJECTIVES: This study aimed to assess the safety and efficacy of class 1C AADs in patients with nonischemic cardiomyopathy (NICM) and implantable cardioverter-defibrillators (ICDs). METHODS: All patients with NICM and an ICD treated with flecainide or propafenone at the Hospital of the University of Pennsylvania between 2014 and 2022 were identified...
March 5, 2024: JACC. Clinical Electrophysiology